Global Wealth Management Investment Advisory Inc. Has $5.92 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Global Wealth Management Investment Advisory Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,691 shares of the company's stock after buying an additional 1,734 shares during the period. Johnson & Johnson makes up 1.2% of Global Wealth Management Investment Advisory Inc.'s holdings, making the stock its 22nd biggest position. Global Wealth Management Investment Advisory Inc.'s holdings in Johnson & Johnson were worth $5,919,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of JNJ. WealthTrak Capital Management LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson in the fourth quarter valued at about $29,000. Conquis Financial LLC bought a new position in Johnson & Johnson in the fourth quarter valued at about $33,000. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson in the fourth quarter valued at about $36,000. Finally, Runnymede Capital Advisors Inc. bought a new position in Johnson & Johnson in the fourth quarter valued at about $38,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.3%

JNJ stock traded down $0.40 during trading on Tuesday, hitting $154.87. The company had a trading volume of 2,533,793 shares, compared to its average volume of 9,039,214. The business has a 50-day moving average of $153.67 and a 200-day moving average of $154.24. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The stock has a market cap of $372.63 billion, a PE ratio of 17.23, a PEG ratio of 2.36 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.36%. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Analysts Set New Price Targets

A number of research firms have issued reports on JNJ. Barclays decreased their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Morgan Stanley lifted their target price on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Raymond James Financial reduced their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.